Zostavax (Zoster Vaccine Live)
The Zostavax litigation consolidates claims that a live-attenuated shingles vaccine caused herpes zoster infection and associated complications, most notably vision loss from zoster ophthalmicus, in patients who received it before a non-live alternative vaccine became available. As a vaccine-injury products case, the litigation's structural core is a causation question distinct from a typical drug or device MDL: because the vaccine itself contains a live, weakened virus, the central scientific dispute is whether a given patient's infection can be attributed to the vaccine strain rather than to a naturally occurring viral reactivation unrelated to vaccination.
With just over a hundred actions active roughly eight years into centralization, this docket sits in a mature, largely individualized phase rather than an early one still contesting foundational general-causation theory. At this stage, resolution risk is driven primarily by case-specific proof — timing between vaccination and symptom onset, viral strain identification where available, and the treating specialist's findings — rather than by an open scientific dispute about whether the vaccine can cause these injuries at all.
Procedural posture for a vaccine-injury claim can also differ from other products-liability litigation depending on how a given claim is framed, which is itself part of the structural picture worth understanding before assuming this docket resolves the way a typical drug-injury MDL does. Cases not resolved through a negotiated mechanism proceed toward remand and individual trial under standard MDL procedure.
Criterica Intelligence's regulated outcomes intelligence is designed to surface exactly this kind of causation-structure distinction — without stating a probability of success or a predicted dollar value for any claim — and applies the same analytical lens to every active MDL, vaccine-injury litigation included. That lens is what allows the platform to compare a docket like this one against a chemical-exposure or device-defect MDL on structural terms rather than headline severity alone.
It alleges that a live-attenuated shingles vaccine caused herpes zoster infection and complications, including vision loss, in vaccine recipients. Claims are centralized before Judge Harvey Bartle in the Eastern District of Pennsylvania.
Because the vaccine itself contains a live, attenuated virus, causation often turns on whether the infection can be traced specifically to the vaccine strain rather than to a naturally occurring reactivation, which shapes the expert record differently than in a chemical-exposure tort.
Zostavax was one of several shingles vaccines used before being succeeded by a non-live alternative, so the affected patient population, and resulting claim volume, is smaller than in dockets involving broadly used consumer drugs or devices.
As a structural matter of causation design and claim-severity variation, tracking procedural posture and resolution pathway the same way it does across every active MDL, without predicting individual case outcomes.
Statistics shown reflect historical or illustrative model outputs derived from real case data. They are not predictions or guarantees of any individual outcome. Litigation results depend on facts, jurisdiction, judge, and counsel, and vary case by case. Model accuracy is subject to selection effects and changing legal dynamics.